Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs)

[1]  C. Zamiri,et al.  Challenges of using closed system transfer devices with biological drug products - An industry perspective. , 2019, Journal of pharmaceutical sciences.

[2]  Yongbin Wei,et al.  Industry Perspective , 2017, IEEE Wirel. Commun..

[3]  Takuto Yamazaki,et al.  Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice , 2017, The Journal of pharmacy and pharmacology.

[4]  G. Winter,et al.  Dose levels in particulate-containing formulations impact anti-drug antibody responses to murine monoclonal antibody in mice. , 2015, Journal of pharmaceutical sciences.

[5]  P. Sessink,et al.  Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents , 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[6]  P. Sessink,et al.  Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[7]  N. Le,et al.  Cancer incidence and adverse pregnancy outcome in registered nurses potentially exposed to antineoplastic drugs , 2010, BMC nursing.

[8]  B. Harrison,et al.  Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  L. Tyler,et al.  Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[10]  Dennis Nowak,et al.  Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations , 2003, International archives of occupational and environmental health.

[11]  T. Sendo,et al.  Particulate contamination of lyophilized amphotericin B preparation during reconstitution process , 2001, Journal of clinical pharmacy and therapeutics.

[12]  L. Trissel,et al.  Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. , 1999, Journal of the American Pharmaceutical Association.

[13]  P. Sessink,et al.  Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? , 1994, Archives of environmental health.

[14]  G. Fruhmann,et al.  Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. , 1994, Occupational and environmental medicine.

[15]  M. Ro̸rth,et al.  Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. , 1992, British journal of industrial medicine.

[16]  P. Sessink,et al.  Occupational exposure to antineoplastic agents at several departments in a hospital , 1992, International archives of occupational and environmental health.

[17]  E. Lyall,et al.  Hazards of glass ampoules. , 1985, British medical journal.

[18]  B. McNeil,et al.  Microparticulate-induced phlebitis. Its prevention by in-line filtration. , 1985, The New England journal of medicine.

[19]  K. Rieche.  Carcinogenicity of antineoplastic agents in man. , 1984, Cancer treatment reviews.

[20]  B. Bivins,et al.  Clearance of 141C3-labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration in beagle dogs. , 1980, Journal of pharmaceutical sciences.

[21]  C. R. Spence,et al.  The incidence of bladder cancer after cyclophosphamide therapy. , 1979, The Journal of urology.

[22]  H. Vainio,et al.  MUTAGENICITY IN URINE OF NURSES HANDLING CYTOSTATIC DRUGS , 1979, The Lancet.

[23]  P. Deluca,et al.  Particulate matter assessment of a clinical investigation on filtration and infusion phlebitis. , 1976, American journal of hospital pharmacy.

[24]  B. Bivins,et al.  Filtration and infusion phlebitis: a double-blind prospective clinical study. , 1975, American journal of hospital pharmacy.

[25]  J. Garvan,et al.  THE HARMFUL EFFECTS OF PARTICLES IN INTRAVENOUS FLUIDS , 1964, The Medical journal of Australia.

[26]  W. Stehbens,et al.  THE BEHAVIOUR OF INTRAVENOUSLY INJECTED PARTICLES OBSERVED IN CHAMBERS IN RABBITS' EARS , 1960 .

[27]  J. Dunning,et al.  An in vitro and in vivo study of glass particles in ampules. , 1947, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[28]  William Jackson,et al.  Overcoming Challenges of Implementing Closed System Transfer Device Clinical In-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates. , 2019, Journal of pharmaceutical sciences.

[29]  M. Joubert,et al.  Silicone Oil Particles in Pre-Filled Syringes with Human Monoclonal Antibody Representative of Real-World Drug Products Did Not Increase Immunogenicity in In Vivo and In Vitro Model Systems. , 2019, Journal of pharmaceutical sciences.

[30]  Yoshinori Tsuji,et al.  The Handling Devised to Reduce the Risk of Leakage from Rubber Stopper at the Time of Preparation of Anticancer Drugs , 2013 .

[31]  P. Sessink,et al.  Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[32]  日本公定書協会.  The Japanese pharmacopoeia , 2001 .